DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives $14.42 Average Price Target from Brokerages

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been assigned an average rating of “Hold” from the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $14.4167.

XRAY has been the subject of several research analyst reports. Barclays began coverage on shares of DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target for the company. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Robert W. Baird upped their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Barrington Research increased their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. Finally, Wells Fargo & Company lifted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th.

DENTSPLY SIRONA Stock Down 2.2%

XRAY opened at $11.54 on Wednesday. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The business has a 50-day moving average of $12.73 and a two-hundred day moving average of $12.41. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -3.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter in the previous year, the company earned $0.26 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Transactions at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier bought 27,555 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the acquisition, the director owned 27,555 shares of the company’s stock, valued at $392,383.20. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director James D. Forbes bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 70,000 shares of company stock worth $956,437. Company insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of DENTSPLY SIRONA by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after acquiring an additional 869,566 shares during the period. First Eagle Investment Management LLC increased its holdings in DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after purchasing an additional 458,744 shares in the last quarter. AQR Capital Management LLC raised its position in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the period. Lazard Asset Management LLC raised its position in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after purchasing an additional 92,868 shares during the period. Finally, Armistice Capital LLC lifted its stake in shares of DENTSPLY SIRONA by 27.2% during the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after purchasing an additional 1,562,000 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.